2,015
Participants
Start Date
June 30, 2008
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
Epirubicin, cyclophosphamide and docetaxel
Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
docetaxel, cyclophosphamide
Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
Dept. of Oncology; Aalborg Sygehus, Aalborg
Dept. of Oncology; Århus Sygehus, Aarhus
Dept. of Oncology; Rigshospitalet, Copenhagen
Dept. of Oncology; Sydvestjysk Sygehus Esbjerg, Esbjerg
Dept. of Oncology; Herlev Hospital, Herlev
Dept. of Oncology; Regionshospitalet Herning, Herning
Dept. of Oncology; Nordsjællands Hospital Hillerød, Hillerød
Dept. of Oncology; Sygehus Syd Næstved, Næstved
Dept. of Oncology; Odense University Hospital, Odense
Dept. of Oncology; Sygehus Øst Roskilde, Roskilde
Dept. of internal medicine; Bornholms Hospital, Rønne
Dept. of Oncology; Vejle Sygehus, Vejle
Dept. of Oncology; Regionshospitalet Viborg, Viborg